INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

NCT05151640 · clinicaltrials.gov ↗

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Diseases, Interstitial

Interventions

DRUG: Nintedanib

Sponsor

Boehringer Ingelheim